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Fig 2. Darier disease, patient 2. Pretreatment (A) and following application of diclofenac
sodium 3% gel twice daily for 3 months (B).
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e90 Lettersand its protein product SERCA2.2 Down-regulation
of ATP2A2 expression can be counteracted by
suppressing the production of prostaglandin E2,
which is an effect of the COX-2 inhibitors.
Considering that DD is caused by a reduction in
the expression of ATP2A2/SERCA2, we propose a
new therapeutic approach using COX inhibitors
such as diclofenac.3
Our observation of benefit from application of
diclofenac sodium 3% gel in 2 patients with DD
seems to support this theory. It would be interesting
to ascertain if similar effects can be achieved
by systemic administration of the nonsteroidal anti-
inflammatory agent and to investigate whether it has
a therapeutic role in other dermatologic diseases
with pathogenesis linked to the COX enzyme
pathway.
Fernando Millan-Parrilla, PhD, Beatriz Rodrigo-
Nicolas, MD, Paula Moles-Poveda, MD, Miquel
Armengot-Carbo, MD, Esther Quecedo-Estebanez,
PhD, and Enrique Gimeno-Carpio, MD
Department of Dermatology, Hospital Arnau de
Vilanova of Valencia, Valencia, Spain
Funding sources: None.
Conflicts of interest: None declared.
Correspondence to: Fernando Millan-Parrilla,
PhD, Department of Dermatology, Hospital
Arnau de Vilanova of Valencia, 12, San
Clemente St. 46015 Valencia, Spain
E-mail: fe.millanp@comv.esREFERENCES
1. Craddock N, Dawson E, Burge S, Parfitt L, Mant B, Roberts Q,
et al. The gene for Darier’s disease maps to chromosome
12q23-q24.1. Hum Mol Genet 1993;2:1941-3.
2. Kamijo M, Nishiyama C, Takagi A, Nakano N, Hara M, Ikeda S,
et al. Cyclooxygenase-2 inhibition restores ultraviolet B-induced
Open access under CC BY-NC-ND license.downregulation of ATP2A2/SERC2 in keratinocytes: possible
therapeutic approach of cyclooxygenase-2 inhibition for treat-
ment of Darier disease. Br J Dermatol 2012;166:1017-22.
3. Maltusch A, R€owert-Huber J, Matthies C, Lange-Asschenfeldt S,
Stockfleth E. Modes of action of diclofenac 3% hyaluronic acid
2.5% in the treatment of actinic keratosis. J Dtsch Dermatol Ges
2011;9:1011-7.
http://dx.doi.org/10.1016/j.jaad.2013.11.033
Lichen striatus associated with etanercept
treatment of rheumatoid arthritis
To the Editor: Lichenoid eruptions are an emerging
adverse event of anti-TNF therapy. They share the
common histopathologic features of a lichenoid
reaction, but present with 3 different clinical pat-
terns: (1) lichen planus-like (LPLE), (2) nonspecific
maculopapular, and (3) psoriasis-like.1 Lichenoid
eruptions with a segmental arrangement have rarely
been observed in the setting of anti-TNF therapy.2,3
We encountered a 70-year-old woman in whom a
linear dermatosis developed 8 months after starting
therapy with etanercept (50 mg/week) for severe
rheumatoid arthritis. The patient had no history of
infection while on therapy and no clinical evidence
of an infection before the onset of the eruption
existed. Her medical history was notable for
hypertension, thyroiditis, dyslipidemia, and diabetes
mellitus, for which she was treated with fosinopril/
hydrochlorothiazide, nebivolol, levothyroxine, ator-
vastatin, and metformin. No changes in the dosing of
these drugs were introduced during the 12 months
preceding initiation of etanercept. Eight months after
starting etanercept treatment, an erythematous,
scaly, papular eruption with a linear arrangement
along Blaschko lines developed over the right side of
her body (Fig 1, A). Microscopic examination of a
biopsy specimen obtained from the leg showed
epidermal orthohyperkeratosis, acanthosis, and a
lichenoid lymphocytic interface dermatitis associ-
ated with a deep lymphocytic infiltrate surrounding
Fig 1. Lichen striatus. A, Erythematous, scaly, papular eruption following the lines of Blaschko
on the right leg. B, Detail of lichenoid lymphocytic interface dermatitis. C, Lymphocytic
infiltrate involving eccrine gland coils (B and C, Hematoxylin-eosin stain; original magnifica-
tions: 3100).
J AM ACAD DERMATOL
VOLUME 70, NUMBER 4
Letters e91eccrine sweat glands (Fig 1, B and C ), that are
features suggestive of lichen striatus (LS). Etanercept
was discontinued and a local steroid treatment
was prescribed. A 7-month follow up showed
regression of skin lesions with secondary
hyperpigmentation.
LS is an uncommon self-limiting lichenoid derma-
tosis following Blaschko lines of the skin. Its etiopa-
thogenesis remains unknown. It has been speculated
that the disease could be due to loss of immune
tolerance induced by an acquired stimulus, resulting
in a cytotoxic reaction toward mutated, post-zygotic
skin cells distributed along Blaschko lines.4 LS is rare
in adults and controversies exist regarding the
differential diagnosis for adult blaschkitis.4 The
patient described here meets the diagnostic criteria
for LS (scaly papular lesions with a segmental
pattern, typical histologic features, recovery with
postinflammatory hyperpigmentation).4
Anti-TNF therapy can exceptionally induce
segmental lichenoid reactions. To our knowledge,
only 1 case of etanercept-induced LPLE following
Blaschko lines and 1 case of adult blaschkitis due to
adalimumab have been reported thus far. In
these cases, as well as in the other cases of lichenoid
eruptions secondary to biologic therapy, anup-regulation of interferon-alfa synthesis following
TNF inhibition has been suggested.1,2 In our case, a
role for a transient (subclinical) infectious episode
cannot be completely excluded, even though there
was no evidence for an associated one. In fact,
patients with rheumatoid arthritis, as the one
presented here, are at higher risk for infection
when treated with biologic agents, such as TNF
inhibitors.5 This infection could cause the expression
of aberrant membrane antigens in susceptible
mutated keratinocytes, thereby triggering the
disease. Finally, a direct toxic effect of the drug on
the abnormal cells distributed along Blaschko lines
can be also hypothesized.
In conclusion, we report what we believe is the
first case of adult LS associated with etanercept
therapy. This observation further expands the
clinical spectrum of lichenoid reactions due to
TNF inhibitors.
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